Analyzing Arcus Biosciences (RCUS) and Its Competitors
Arcus Biosciences (NYSE: RCUS) is one of 548 public companies in the “Pharmaceutical preparations” industry, but how does it contrast to its rivals? We will compare Arcus Biosciences to similar businesses based on the strength of its dividends, institutional ownership, analyst recommendations, risk, profitability, earnings and valuation.
This table compares Arcus Biosciences and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Arcus Biosciences Competitors||-1,760.46%||-120.17%||-28.09%|
This table compares Arcus Biosciences and its rivals top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Arcus Biosciences||$8.35 million||-$49.59 million||-7.85|
|Arcus Biosciences Competitors||$2.15 billion||$228.73 million||-3.52|
Arcus Biosciences’ rivals have higher revenue and earnings than Arcus Biosciences. Arcus Biosciences is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Institutional & Insider Ownership
49.1% of Arcus Biosciences shares are held by institutional investors. Comparatively, 46.3% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 14.9% of shares of all “Pharmaceutical preparations” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
This is a breakdown of recent ratings and target prices for Arcus Biosciences and its rivals, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Arcus Biosciences Competitors||4546||13020||27670||994||2.54|
Arcus Biosciences presently has a consensus target price of $21.00, indicating a potential upside of 87.00%. As a group, “Pharmaceutical preparations” companies have a potential upside of 58.50%. Given Arcus Biosciences’ stronger consensus rating and higher probable upside, equities research analysts plainly believe Arcus Biosciences is more favorable than its rivals.
Arcus Biosciences beats its rivals on 7 of the 12 factors compared.
Arcus Biosciences Company Profile
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing cancer immunotherapies in the United States. It is developing various products for treating solid tumors, including AB928, an adenosine receptor antagonist that is in Phase I clinical trial; AB680, a CD73 inhibitor; AB122, an anti-PD-1 antibody that is Phase I clinical trial; and AB154, an anti-TIGIT antibody. The company was founded in 2015 and is headquartered in Hayward, California.
Receive News & Ratings for Arcus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.